Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023

BUY
$14.09 - $19.87 $104,871 - $147,892
7,443 New
7,443 $118,000
Q4 2018

Feb 06, 2019

SELL
$3.94 - $9.7 $243,003 - $598,257
-61,676 Closed
0 $0
Q3 2018

Oct 16, 2018

BUY
$8.6 - $11.26 $530,413 - $694,471
61,676 New
61,676 $584,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Essex Investment Management CO LLC Portfolio

Follow Essex Investment Management CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Essex Investment Management CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Essex Investment Management CO LLC with notifications on news.